Tazarotene
Who holds supplier records for Tazarotene? 4 organisations hold a current record for Tazarotene: an active US FDA Type II Drug Master File. A further 3 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (1), Italy (1), France (1) and Israel (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Tazarotene: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/tazarotene
Reading the evidence
- 4 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 4 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Tazarotene expires 11 May 2038. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (4)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Tazarotene. Country is the organisation's recorded country, not necessarily the manufacturing site.
- ALIVUS LIFE SCIENCES LTDIndia Company GMP cert on recordActive DMF 21422 · latest filing Mar 2008
- OLON SPAItaly Company GMP cert on recordActive DMF 29600 · latest filing Jul 2015
- PCASFrance Company GMP cert on recordActive DMF 25161 · latest filing Jul 2011
- Taro Pharmaceutical Industries Ltd.Israel Company GMP cert on recordActive DMF 28470 · latest filing Oct 2014
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (3)
Organisations whose Type II DMFs for Tazarotene are no longer active. These show a past filing, not current supply.
Show all 3 historical records
- Piramal Healthcare (Canada) LimitedCanada · Inactive DMF 24874 · filed Apr 2011
- India · Inactive DMF 20063 · filed Dec 2006
- Germany · Inactive DMF 19089 · filed Jan 2006
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (18 listed products contain Tazarotene). The latest listed patent expires 11 May 2038. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Tazarotene is a third-generation prescription topical retinoid used for the treatment of psoriasis, acne, and sun-damaged skin. It works by modulating skin cell growth and reducing inflammation.
Chemical identity
- IUPAC name
- ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate
- Canonical SMILES
- CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C
- InChIKey
- OGQICQVSFDPSEI-UHFFFAOYSA-N
- Synonyms
- Tazorac API, agn-190168, agn190168, arazlo, avage, duobrii component tazarotene, idp-118 component tazarotene, idp-123, tazorac
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Retinoid
- Chemical structure
- Retinoids
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Tazarotene?
4 organisations hold an active US FDA Type II Drug Master File or a CEP for Tazarotene: ALIVUS LIFE SCIENCES LTD (India), OLON SPA (Italy), PCAS (France) and Taro Pharmaceutical Industries Ltd. (Israel). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Tazarotene Drug Master Files are active?
ALIVUS LIFE SCIENCES LTD (DMF 21422), OLON SPA (DMF 29600), PCAS (DMF 25161) and Taro Pharmaceutical Industries Ltd. (DMF 28470). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Tazarotene records mean?
3 organisations have only inactive Type II DMFs for Tazarotene. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Tazarotene?
Yes. The latest patent listed for an approved US product containing Tazarotene expires 11 May 2038, across 18 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Tazarotene supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Tazarotene?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.